Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. BioMérieux
  6. Summary
    BIM   FR0013280286

BIOMÉRIEUX

(BIM)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
09/20/2021 09/21/2021 09/22/2021 09/23/2021 09/24/2021 Date
111.95(c) 111.7(c) 110.1(c) 109(c) 107.35 Last
94 075 77 269 85 705 87 785 94 780 Volume
-2.31% -0.22% -1.43% -1.00% -1.51% Change
More quotes
Estimated financial data (e)
Sales 2021 3 180 M 3 724 M 3 724 M
Net income 2021 464 M 543 M 543 M
Net cash position 2021 170 M 199 M 199 M
P/E ratio 2021 27,8x
Yield 2021 0,56%
Sales 2022 3 179 M 3 722 M 3 722 M
Net income 2022 410 M 480 M 480 M
Net cash position 2022 448 M 524 M 524 M
P/E ratio 2022 31,4x
Yield 2022 0,55%
Capitalization 12 899 M 15 104 M 15 104 M
EV / Sales 2021 4,00x
EV / Sales 2022 3,92x
Nbr of Employees 12 800
Free-Float 35,7%
More Financials
Company
Biomerieux SA is a France-based company that specializes in the field of in-vitro diagnostics for medical and industrial applications. The Company designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The Company also... 
More about the company
Ratings of bioMérieux
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about BIOMÉRIEUX
09/21BioMérieux Achieves First-Ever AOAC INTERNATIONAL Approval for PCR Multiplex Detection ..
CI
09/13BIOMERIEUX : A survey in 5 European countries about sepsis demonstrates the lack of awaren..
PU
09/13BIOMERIEUX : A survey in 5 European countries about sepsis demonstrates the lack of awaren..
PU
09/02BIOMERIEUX : Notice of publication of the 2021 half-year financial report
PU
09/01BIOMERIEUX : First Half 2021 results - September 1, 2021
PU
09/01BIOMERIEUX : Résultats semestriels au 30 juin 2021 - 1er September 2021
PU
09/01European stocks make strong start to September, record high in sight
RE
09/01GLOBAL MARKETS LIVE : Getlink, Intuit, CrowdStrike, Xiaomi, Merck...
09/01BIOMERIEUX : BioMérieux – First-Half 2021 Results
PU
06/30BIOMERIEUX : France's BioMérieux To Invest $10 Million In US-Based Specific Diagnostics
MT
06/29BIOMERIEUX : In the fight against Antimicrobial Resistance, bioMérieux and Specific Diagno..
PU
06/29Specific Diagnostics, LLC announced that it expects to receive $10 million in funding f..
CI
06/24BIOMERIEUX : BioMérieux launches EPISEQ® SARS-COV-2, a cloud-based software application fo..
PU
06/23BIOMERIEUX : Annual Report 2020
PU
06/04BIOMÉRIEUX : Ex-dividend day for final dividend
FA
More news
News in other languages on BIOMÉRIEUX
09/16AVIS D'ANALYSTES DU JOUR : Air France KLM, Eurofins, Infineon, Idorsia, Ab Inbev, Getlink,..
09/16Bolsa de Madrid: ¿China deja de ser atractiva?
09/16STOCK MARKET PARIS : Infréquentable, la Chine ?
09/13BIOMERIEUX : Une enquête au sujet du sepsis menée dans 5 pays européens démontre le manque..
09/13BIOMERIEUX : Une enquête au sujet du sepsis menée dans 5 pays européens démontre le manque..
More news
Analyst Recommendations on BIOMÉRIEUX
More recommendations
Stock Trading Strategies
BIOMÉRIEUX - 07/09
Expectation of a turn-around
BUY
More Stock Trading Analysis
Chart BIOMÉRIEUX
Duration : Period :
bioMérieux Technical Analysis Chart | BIM | FR0013280286 | MarketScreener
Technical analysis trends BIOMÉRIEUX
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 109,00 €
Average target price 113,60 €
Spread / Average Target 4,22%
EPS Revisions
Managers and Directors
Alexandre Mérieux Chairman & Chief Executive Officer
Guillaume Bouhours EVP-Finance, Purchasing & Information Systems
Alain Mérieux Founding Chairman
François Lacoste Executive Director-Research & Development
Mark Miller Executive Director-Medical Affairs
Sector and Competitors